Lens autofluorescence increases with the age of the subject, and the fluorophores responsible are associated with cataract, retinopathy, and other complications of diabetes. We built a scanning confocal lens fluorescence biomicroscope suitable for routine clinical measurement of lens autofluorescence and light scattering and report data from 127 healthy subjects.
Method:
The fluorescence biomicroscope focuses a beam of light from a blue light-emitting diode on the lens and measures fluorescent green light and blue scattered light using a sensitive silicon photomultiplier. The system includes a target fixation light and a video camera for alignment and automatic pupil tracking. Under software control, a volume of measurement is scanned from behind the posterior lens capsule, through the lens to the aqueous humor, and then back again. Software computes the average ratio of lens autofluorescence to scattered light in the central portion of the lens. Self-reported healthy nondiabetic subjects were examined by an optometrist; if their eyes were healthy and without significant cataract, they were entered into the study.
Results:
Valid lens autofluorescence data were collected from 127 subjects between 21 and 70 years of age. A linear model for lens autofluorescence intensity with age was highly statistically significant, and the improvement in fit for higher-order polynomial models was not statistically significant. The ratio of lens autofluorescence to light scatter was also calculated; regression analysis showed significant curvature for the relationship of the fluorescence ratio to age, so a nonlinear model was used to estimate the mean ratio of autofluorescence to scatter and its prediction intervals as a function of age.
Conclusions:
Our observation of a strongly significant linear regression of fluorescence intensity with age of the subjects agrees with the results from previous studies, as does a nonlinear model for the fluorescence ratio. The fluorescence biomicroscope enables the clinician to identify patients with fluorescence ratio significantly higher than expected for their age.
RegnauldJ.Sur la fluorescence des milieux de l'oeil chez l'homme et quelques mammiferes. L'Institut.1858;26: 410.
2.
SetschenowJ.Ueber die Fluorescenz der durchsichtigen Augenmedien beim Menschen und einigen anderen Säugethieren. Albrecht Graefes Archiv Ophthalmologie.1859;5 (2): 205–10.
3.
VannasMWilskaA.Eine Methode zur Meesung der Fluorenzenz (lor lehnden menschlichen Augenlinee und eine Untersuchung iiber ifire Abhiingigkeit. Alter Klin Monatabl Augenh.1935;95: 53–64.
4.
KlangG.Measurements and studies of the fluorescence of the human lens in vivo. Acta Ophthalmol.1948;31: 1–152.
5.
DyerDGBlackledgeJAKatzBMHullCJAdkissonHDThorpeSRLyonsTJBaynesJW, The Maillard reaction in vivo. Z Ernahrungswiss.1991;30 (1): 29–45.
6.
MonnierVMCeramiA.Nonenzymatic browning in vivo: Possible process for aging of long-lived proteins. Science.1981;211 (4481): 491–3.
7.
FlemingTHHumpertPMNawrothPPBierhausA.Reactive metabolites and AGE/RAGE-mediated cellular dysfunction affect the aging process: A mini-review. Gerontology.2011;57 (5): 435–43.
8.
BastaGSchmidtAMDe CaterinaR.Advanced glycation end products and vascular inflammation: Implications for accelerated atherosclerosis in diabetes. Cardiovasc Res.2004;63 (4): 582–92.
9.
CooperME, Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease. Am J Hypertens.2004;17 (12 Pt 2): 31S–38S.
10.
MendezJDXieJAguilar-HernandezMMendez-ValenzuelaV.Molecular susceptibility to glycation and its implication in diabetes mellitus and related diseases. Mol Cell Biochem.2010;344 (1–2): 185–93.
11.
ThorpeSRBaynesJW, Role of the Maillard reaction in diabetes mellitus and diseases of aging. Drugs Aging.1996;9 (2): 69–77.
12.
MeerwaldtRLinksTZeebregtsCTioRHillebrandsJLSmitA.The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes. Cardiovasc Diabetol.2008;7: 29.
13.
MonnierVMSellDRGenuthS.Glycation products as markers and predictors of the progression of diabetic complications. Ann N Y Acad Sci.2005;1043: 567–81.
14.
GarlickRLMazerJSChylackLTJrTungWHBunnHF, Nonenzymatic glycation of human lens crystallin. Effect of aging and diabetes mellitus. J Clin Invest.1984;74 (5): 1742–9.
15.
LutzeMBresnickGH, Lenses of diabetic patients “yellow” at an accelerated rate similar to older normals. Invest Ophthalmol Vis Sci.1991;32 (1): 194.
16.
SensiMPricciFPuglieseCDe RossiMGCeliFSCristinaAMoranoSAndreaniDDi MarioU. Enhanced nonenzymatic glycation of eye lens proteins in experimental diabetes mellitus: An approach for the study of protein alterations as mediators of normal aging phenomena. Arch Gerontol Geriatr.1992;15Suppl 1: 333–7.
17.
Van BoekelMAHoendersHJ, Glycation of crystallins in lenses from aging and diabetic individuals. FEBS Lett.1992;314 (1): 1–4.
18.
NakayamaHMitsuhashiTKuwajimaSAokiSKurodaYItohTNakagawaS.Immunochemical detection of advanced glycation end products in lens crystallins from streptozocin-induced diabetic rat. Diabetes.1993;42 (2): 345–50.
19.
ZarinaSZhaoHRAbrahamEC, Advanced glycation end products in human senile and diabetic cataractous lenses. Mol Cell Biochem.2000;210 (1–2): 29–34.
20.
GulARahmanMASalimASimjeeSU, Advanced glycation end products in senile diabetic and nondiabetic patients with cataract. J Diabetes Complications.2009;23 (5): 343–8.
21.
NagarajRHLinetskyMStittAW, The pathogenic role of Maillard reaction in the aging eye. Amino Acids.2012;42 (4): 1205–20.
22.
HashimZZarinaS.Advanced glycation end products in diabetic and non-diabetic human subjects suffering from cataract. Age (Dordr).2011;33 (3): 377–84.
23.
BleekerJCvan BestJAVrijLvan der VeldeEAOosterhuisJA, Autofluorescence of the lens in diabetic and healthy subjects by fluorophotometry. Invest Ophthalmol Vis Sci.1986;27 (5): 791–4.
24.
Van WirdumEMotaMCvan BestJALeiteEKappelhofJPde AbreuJR FariaPaulLCMartinsJ FreitasOosterhuisJAMarquesA.Lens transmission and autofluorescence in renal disease. Ophthalmic Res.1988;20 (5): 317–26.
25.
OcchipintiJRMosierMABursteinNL, Autofluorescence and light transmission in the aging crystalline lens. Ophthalmologica.1986;192 (4): 203–9.
26.
LyonsTJBailieKEDyerDGDunnJABaynesJW, Decrease in skin collagen glycation with improved glycemic control in patients with insulin-dependent diabetes mellitus. J Clin Invest.1991;87 (6): 1910–5.
27.
MeerwaldtRHartogJWGraaffRHuismanRJLinksTPden HollanderNCThorpeSRBaynesJWNavisGGansROSmitAJ, Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol.2005;16 (12): 3687–93.
28.
JanuszewskiASSachithanandanNKarschimkusCO'NealDNYeungCKAlkatibNJenkinsAJ, Non-invasive measures of tissue autofluorescence are increased in type 1 diabetes complications and correlate with a non-invasive measure of vascular dysfunction. Diabet Med.2012;29 (6): 726–33.
29.
KurzelRBWolbarshtMLYamanashiBS, Spectral studies on normal and cataractous intact human lenses. Exp Eye Res.1973;17 (1): 65–71.
30.
LiangJNRossiMT, In vitro non-enzymatic glycation and formation of browning products in the bovine lens alpha-crystallin. Exp Eye Res.1990;50 (4): 367–71.
31.
DyerDGBlackledgeJAThorpeSRBaynesJW, Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem.1991;266 (18): 11654–60.
32.
KameiAKatoM.Contribution of glycation to human lens coloration. Chem Pharm Bull (Tokyo).1991;39 (5): 1272–6.
33.
AbikoTAbikoAIshikoSTakedaMHoriuchiSYoshidaA.Relationship between autofluorescence and advanced glycation end products in diabetic lenses. Exp Eye Res.1999;68 (3): 361–6.
34.
DasBKSunTXAkhtarNJChylackLTJrLiangJJ, Fluorescence and immunochemical studies of advanced glycation-related lens pigments. Invest Ophthalmol Vis Sci.1998;39 (11): 2058–66.
35.
PokupecRKalauzMTurkNTurkZ.Advanced glycation endproducts in human diabetic and non-diabetic cataractous lenses. Graefes Arch Clin Exp Ophthalmol.2003;241 (5): 378–84.
36.
FrankeSDawczynskiJStrobelJNiwaTStahlPSteinG.Increased levels of advanced glycation end products in human cataractous lenses. J Cataract Refract Surg.2003;29 (5): 998–1004.
37.
RanjanMBeeduSR, Spectroscopic and biochemical correlations during the course of human lens aging. BMC Ophthalmol.2006;6: 10.
38.
JacobsRKrohnDL, Variations in fluorescence characteristics of intact human crystalline lens segments as a function of age. J Gerontol. Nov1976;31 (6): 641–7.
39.
ChengRLinBOrtwerthBJ, Separation of the yellow chromophores in individual brunescent cataracts. Exp Eye Res.2003;77 (3): 313–25.
40.
KameiA.Glycation and insolubility of human lens protein. Chem Pharm Bull (Tokyo).1992;40 (10): 2787–91.
41.
YanoMMatsudaSBandoYShimaK.Lens protein glycation and the subsequent degree of opacity in streptozotocin-diabetic rats. Diabetes Res Clin Pract.1989;7 (4): 259–62.
42.
OimomiMMaedaYHataFKitamuraYMatsumotoSBabaSIgaTYamamotoM.Glycation of cataractous lens in nondiabetic senile subjects and in diabetic patients. Exp Eye Res.1988;46 (3): 415–20.
43.
LyonsTJSilvestriGDunnJADyerDGBaynesJW, Role of glycation in modification of lens crystallins in diabetic and nondiabetic senile cataracts. Diabetes.1991;40 (8): 1010–5.
44.
SiikSAiraksinenPJTuulonenAAlankoHINieminenH.Lens autofluorescence in healthy individuals. Acta Ophthalmol (Copenh).1991;69 (2): 187–92.
45.
Van BestJAVrijLOosterhuisJA, Lens transmission of blue-green light in diabetic patients as measured by autofluorophotometry. Invest Ophthalmol Vis Sci.1985;26 (4): 532–6.
46.
MosierMAOcchipintiJRBursteinNL, Autofluorescence of the crystalline lens in diabetes. Arch Ophthalmol.1986;104 (9): 1340–3.
47.
Van WirdumEvan BestJBruiningGJde BeaufortCOosterhuisJ.Blood-retinal and blood-aqueous barrier permeability, lens autofluorescence and transmission in insulin-dependent diabetic youngsters. Graefes Arch Clin Exp Ophthalmol.1989;227 (1): 26–9.
48.
LarsenMKjerBBendtsonIDalgaardPLund-AndersenH.Lens fluorescence in relation to metabolic control of insulin-dependent diabetes mellitus. Arch Ophthalmol.1989;107 (1): 59–62.
49.
KesselLSanderBDalgaardPLarsenM.Lens fluorescence and metabolic control in type 1 diabetic patients: A 14 year follow up study. Br J Ophthalmol.2004;88 (9): 1169–72.
50.
SparrowJMBronAJBrownNANeilHA, Autofluorescence of the crystalline lens in early and late onset diabetes. Br J Ophthalmol.1992;76 (1): 25–31.
51.
MoriFIshikoSAbikoTKitayaNKatoYKannoHYoshidaA.Changes in corneal and lens autofluorescence and blood glucose levels in diabetics: Parameters of blood glucose control. Curr Eye Res.1997;16 (6): 534–8.
52.
MunchICLarsenMBorch-JohnsenKGlumerCLund-AndersenHKesselL.Cumulative glycaemia as measured by lens fluorometry: Association with retinopathy in type 2 diabetes. Diabetologia.2011;54 (4): 757–61.
53.
LarsenMKjerBBendtsonIDalgaardPLund-AndersenH.Lens fluorescence in relation to nephropathy in insulin-dependent diabetes mellitus. Graefes Arch Clin Exp Ophthalmol.1992;230 (1): 6–10.
54.
YuNTKrantzBSEppsteinJAIgnotzKDSamuelsMALongJRPriceJ.Development of a noninvasive diabetes screening device using the ratio of fluorescence to Rayleigh scattered light. J Biomed Opt.1996;1 (3): 280–8.
